Clinical Trial Detail

NCT ID NCT01875250
Title Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM

Age Groups: senior adult

No variant requirements are available.